4103 ORAL Doxorubicin Can Be Safely Omitted From the Treatment of Stage ll/lll, Intermediate Risk Histology Wilms Tumour – Results of the SIOP WT 2001 Randomised Trial, on Behalf of the SIOP Renal Tumours Study Group

2011 ◽  
Vol 47 ◽  
pp. S284-S285 ◽  
Author(s):  
K. Pritchard-Jones ◽  
N. Graf ◽  
C. Bergeron ◽  
B. de Camargo ◽  
M. van den Heuvel ◽  
...  
2006 ◽  
Vol 42 (15) ◽  
pp. 2554-2562 ◽  
Author(s):  
Christopher Mitchell ◽  
Kathy Pritchard-Jones ◽  
Rosemary Shannon ◽  
Carolyn Hutton ◽  
Suzanne Stevens ◽  
...  

Heart Asia ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. e011201
Author(s):  
Yotsawee Chotechuang ◽  
Arintaya Phrommintikul ◽  
Srun Kuanprasert ◽  
Roungtiva Muenpa ◽  
Jayanton Patumanond ◽  
...  

BackgroundThe benefit of an early coronary intervention after streptokinase (SK) therapy in low to intermediate-risk patients with ST-elevation myocardial infarction (STEMI) still remains uncertain. The current study aimed to evaluate the cardiovascular outcomes of early versus delayed coronary intervention in low to intermediate-risk patients with STEMI after successful therapy with SK.MethodsWe randomly assigned low to intermediate Global Registry of Acute Coronary Events risk score to patients with STEMI who had successful treatment with full-dose SK at Lampang Hospital and Maharaj Nakorn Chiang Mai Hospital into early and delayed coronary intervention groups. The primary endpoints were 30-day and 6-month composite cardiovascular outcomes (death, rehospitalised with acute coronary syndrome, rehospitalised with heart failure and stroke).ResultsOne hundred and sixty-two patients were included in our study. At the 30 days, composite cardiovascular outcomes were 4.9% in the early coronary intervention group and 2.5% in the delayed group (p=0.682). At the 6 months, the composite cardiovascular outcomes were 16.1% in the early group and 6.2% in the delayed group (p=0.054).ConclusionsThe delayed coronary intervention (>24 hours) in low to intermediate STEMI after successful therapy with SK did not increase in short and long-term cardiovascular events compared with an early coronary intervention.Trial registration numberNCT02131103.


1995 ◽  
Vol 36 (3) ◽  
pp. 254-260 ◽  
Author(s):  
C. Hugosson ◽  
R. Nyman ◽  
B. Jacobsson ◽  
H. Jorulf ◽  
K. Sackey ◽  
...  

Eighteen children aged 6 months to 12 years with 20 solid renal tumours; 13 Wilms' tumours (WT), 2 clear cell sarcomas of the kidney, 1 malignant rhabdoid tumour of the kidney and 2 cases of bilateral nephroblastomatosis with Wilms' tumour underwent evaluation with US, CT and MR imaging. Contrast-enhanced CT and non-enhanced MR were equally accurate in determining the size and origin of the tumour but were unreliable in separation of stages I, II and III. US could only accurately assess the size of the tumours. MR characteristics varied somewhat between WTs and non-WTs but contrast-enhanced MR imaging might be useful for separation of WTs from nephroblastomatosis.


Sign in / Sign up

Export Citation Format

Share Document